AstraZeneca-Singapore establish strategic partnerships to improve health through innovation

AstraZeneca enters strategic partnerships with leading Singapore healthcare innovators and organisations to leverage AI, big data and precision medicine to help people with diabetes, heart disease and cancer, aligned with Singapore’s Smart Nation efforts.
 

On 13 February, AstraZeneca signed the Memorandums of Understanding (MOUs) at the Singapore Treasury, in the presence of Singapore’s Minister for Trade and Industry, Mr. Chan Chun Sing, Swedish Ambassador to Singapore, H.E. Mr. Niclas Kvarnström and H.E. Mrs. Kara Owen, British High Commissioner to Singapore. 

AstraZeneca signed these partnerships with Singapore’s AI start-up eko.ai, the SingHealth Duke-NUS Academic Medical Centre (AMC) and the Agency for Science, Technology and Research (A*STAR) to drive better health outcomes and create new economic opportunities in Singapore by leveraging artificial intelligence (AI), big data and genomics.

Along with our partners, AstraZeneca aims to support and contribute to Singapore’s innovation initiatives, such as the National AI Strategy, which is a key step in Singapore’s aim to becoming a Smart Nation. By supporting the growth of talent and skills, and speeding up the deployment of digital technology, these partnerships will advance Singapore’s position as a global hub for cutting edge biomedical and health science innovation and create economic opportunities.
 

Standing from left to right: Deputy Chief Executive (Research) of A*STAR, Professor Andy Hor; Senior Vice President of AstraZeneca Asia Area, Ms. Jo Feng; Swedish Ambassador to Singapore, H.E. Mr. Niclas Kvarnström; Minister for Trade and Industry, Mr. Chan Chun Sing; British High Commissioner to Singapore, H.E. Mrs. Kara Owen.

Seated from left to right: Executive Director of A*STAR, Professor Patrick Tan; Co-Founder of eko.ai, Dr. Carolyn Lam; Country President of AstraZeneca Singapore, Mr. How Ti Hwei; Group Director (Research) of SingHealth, A/Professor Tan Say Beng; Senior Vice Dean (Research) of Duke-NUS Medical School, Professor Patrick Casey.
 

H.E. Mr. Niclas Kvarnström, Swedish Ambassador to Singapore, said “In Sweden we have a long tradition of close collaboration between government, academia and industry for innovation that delivers tangible benefits where it matters most: to people’s lives. I am proud that AstraZeneca, which has been a cornerstone of Swedish healthcare innovation for decades, and its Singapore partners bring this vision into practice by applying their world-class expertise to improve the lives of people.”

H.E. Mrs. Kara Owen, British High Commissioner to Singapore, said, “The UK has a world-class health and life sciences ecosystem that puts it at the forefront of digital health and medical technology breakthroughs. Our strong public-private ethos continues to drive the next generation of life-changing treatments, cutting-edge technologies and customer-first services – not just in the UK but worldwide. This collaboration between British-Swedish AstraZeneca, eko.ai, the SingHealth Duke-NUS Academic Medical Centre (AMC) and A*STAR is one brilliant example of the many forward-looking and innovative collaborations between the UK and Singapore.”

 

Good health is essential to personal development and economic prosperity. We are extremely encouraged by the bold vision from the Singapore government to build a Smart Nation and use cutting-edge technology to help people live healthier, happier lives. We are excited to partner with Singapore’s best healthcare innovators and contribute our scientific and bioinformatics capabilities to the Singaporean biomedical ecosystem, which we now consider an important player in our growing global network of health innovation hubs.

Jo Feng Senior Vice President Asia Area, AstraZeneca

The partnerships will also lead to better health outcomes for the people of Singapore, by using technology to identify risk factors for disease prevention and earlier diagnosis, and to improve the treatment and management of chronic diseases such as diabetes and cancer.

In Singapore’s National AI Strategy, chronic disease prediction and management has been identified as one of five key National AI projects. As a global, science-led biopharmaceutical company AstraZeneca is a well-positioned partner for Singapore’s Smart Nation efforts.

Through AstraZeneca’s strategic R&D centres in Sweden, the UK and the US, AI, data science and digital technology are applied to accelerate R&D, personalise treatment, and improve patient outcomes as well as healthcare delivery.

AstraZeneca has been active in developing healthcare innovation partnerships in Europe and Emerging Markets such as China, Russia and Argentina. This has led to the creation of AstraZeneca health innovation hubs around the world, which are a unique opportunity for our Singaporean partners to showcase their world-class solutions and connect with leading biomedical innovation ecosystems abroad.

Together with our partners, AstraZeneca aims to transform healthcare and give more patients access to new digital healthcare solutions that can revolutionise the management of challenging diseases such as cancer, diabetes, heart failure and respiratory diseases.

-       End -

 

From our partners:

James Hare, Co-founder and CEO, eko.ai, said, “We look forward to partnering with AstraZeneca to continue developing our technology and applying it to real-world, patient settings, while learning from AstraZeneca’s global expertise and existing relationships across the continuum for heart failure management from prevention to treatment.”

Professor Thomas Coffman, Dean of Duke-NUS Medical School, said, “The SingHealth Duke-NUS AMC draws on the collective strengths of SingHealth and Duke-NUS Medical School, integrating clinical care, research and education to pursue excellence in healthcare. We look forward to bringing these strengths to the partnership with AstraZeneca and help deliver lasting benefits to communities in Singapore, with a focus on diseases that are prevalent here and across the region, such as cardiovascular, kidney and metabolic diseases, as well as cancers that are common within the Asian population.”

Professor Wong Tien Yin, Deputy Group CEO (Research and Education), SingHealth, and Vice Dean, Office of Academic & Clinical Development, Duke-NUS said, “Public-private sector partnerships between the healthcare sector and biomedical industry are crucial to bring research from bench to bedside. We look forward to developing a meaningful partnership with AstraZeneca that is aimed at improving clinical outcomes for diseases that affect Singaporeans and communities in the region. For example, the use of data analytics and real-world evidence generation will enable us to predict disease risk and therapeutic outcomes so that we can institute timely clinical intervention and tailor treatment plans for patients.”

Professor Patrick Tan Boon Ooi, Director, A*STAR Precision Medicine Office, and Executive Director, A*STAR’s Genome Institute of Singapore said: “This collaboration is testament to the importance of global partnerships, and it also demonstrates Singapore’s attractiveness for the development of health tech and biopharmaceutical sectors. A*STAR will continue to support this high growth sector through public-private sector partnership in R&D and innovation driven efforts.”

tags

  • Partnering